Effects of AffronEye®/ Crocuvis+® on Dry Eye Syndrome
1 other identifier
interventional
204
1 country
1
Brief Summary
Previous research has demonstrated the effectiveness of AFFRONEYE® / CROCUVIS+® dietary supplement, based on saffron extract, in the proper functioning of visual health, for example, against the development of glaucoma. The main objective of this study is to compare the results of clinical tests that evaluate signs and symptoms for the diagnosis of dry eye, between two groups (some that take the dietary supplement and others a placebo), in a sample of university workers and students who suffer from dry eye.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 22, 2024
CompletedFirst Posted
Study publicly available on registry
February 5, 2024
CompletedStudy Start
First participant enrolled
October 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2026
ExpectedApril 1, 2025
March 1, 2025
7 months
January 22, 2024
March 26, 2025
Conditions
Outcome Measures
Primary Outcomes (7)
Changes from baseline dry eye symptoms at 28, 56 and 84 days
Measured with Ocular Surface Disease Index (OSDI, adapted version to spanish). It consists of 12 items that assess symptoms, functional limitations, and environmental factors related to dry eye. The score ranges from 0 to 100 (worst). Each item is evaluated on a 4-point Likert scale (from 0 to 4). The final score is obtained from (the sum of scores for all questions answered x 25) and divide to total number of questions answered (do not included questions answered N/A); dry eye symptoms are considered from ≥ 13 points.
0 (baseline), 28, 56 and 84 days
Changes with respect to baseline NIBUT at 28, 56 and 84 days
Non-Invasive tear BreakUp Time (NIBUT). It is measured with the Keratograph 5M topographer. It is used to assess tear film stability. It is a non-invasive method to observe and detect the tear film break-up time (measured in seconds). In this case, fluorescein staining can be dispensed with, thus eliminating any influence it may have on the tear film and the results. The region and time course of tear film rupture are automatically measured without user intervention. The software analyses the Placido projecting rings on the tear film and automatically detects any distortion or discontinuity in the reflected annular pattern. The results are recorded with respect to time and space, and translated into a colour-coded map. A positive finding has been reported to be a value \<10 s.
0 (baseline), 28, 56 and 84 days
Changes with respect to baseline TMH at 28, 56 and 84 days
Tear Meniscus Height (TMH). It is measured with the Keratograph 5M topographer. It assesses the height of the lacrimal meniscus (measured in millimetres). Firstly, it provides information on the secretory capacity of the main lacrimal gland and secondly, it may indicate a high evaporation rate, which may, for example, be due to an insufficient lipid layer. It is measured with a ruler from the point of the lower lid margin (below the centre of the pupil) to the upper edge of the lacrimal meniscus. A positive finding has been reported to be a value \<0.2 mm.
0 (baseline), 28, 56 and 84 days
Changes with respect to baseline ocular surface stainings at 28, 56 and 84 days
Ocular surface stains are used to assess epithelial damage to the cornea, conjunctiva, and lid margin. To assess corneal epithelial damage, a fluorescein strip is wet with saline, and a drop is instilled inside the lower temporal lid. Optimal viewing is 1-3 minutes after instillation. A positive result is \>5 corneal spots. To assess conjunctival and lid margin damage, a lissamine green strip is wet with saline, and a drop is instilled inside the lower temporal lid. The observation should occur between 1 and 4 min postinstillation. To assess conjunctival damage, a positive score is \> 9 conjunctival spots. To assess lid margin damage, ≥2 mm in length and/or ≥25% sagittal width is a positive score.
0 (baseline), 28, 56 and 84 days
Changes with respect to baseline lipid layer of the tear film at 28, 56 and 84 days
The thickness of the lipid layer is not uniform throughout its structure and is examined by observing an interferential phenomenon with Keratograph 5M topographer. The ideal pattern is yellow to blue color at around 80-100nm. If excessively colored patterns are observed, this refers to a greater lipid film thickness \>100nm. If, on the other hand, the pattern is gray-white, it indicates a thin or absent lipid layer, causing greater evaporation.
0 (baseline), 28, 56 and 84 days
Changes with respect to baseline MGD at 28, 56 and 84 days
Meibomian Gland Dysfunction (MGD). The morphological changes of these glands are evaluated using the Keratograph 5M topographer using integrated infrared diodes that allow illumination of the everted eyelids. The Meibomian glands are located in the tarsal conjunctiva of the upper and lower eyelids and have the function of producing an oily substance (meibum), which forms the lipid layer of the tear film, protecting it against evaporation of its aqueous phase. The number of meibomian glands should be evaluated in the photographs taken; the larger the area without glands, the greater the DGM.
0 (baseline), 28, 56 and 84 days
Changes from baseline osmolarity at 28, 56 and 84 days
Measured with the Tearlab osmometer. A positive result is considered to be ≥308 mOsm/L in either eye or an interocular difference \>8 mOsm/L.
0 (baseline), 28, 56 and 84 days
Study Arms (2)
Saffron extract (Crocus sativus)
EXPERIMENTALDaily intake of one tablet for 84 days.
Placebo
PLACEBO COMPARATORDaily intake of one tablet for 84 days. This tablet is organoleptically indistinguishable from the experimental tablet.
Interventions
Daily intake of one tablet for 84 days.
Eligibility Criteria
You may qualify if:
- Have dry eye according to the diagnostic criteria established by the Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS).
You may not qualify if:
- Pathology of the anterior ocular surface under treatment (such as conjunctivitis, keratitis, among others).
- Take any type of dietary supplements, with or without botanical components in the last month.
- Pregnancy or breastfeeding (also excludes recent pregnancy within the last 3 months) and women planning to become pregnant.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Alicantelead
- Pharmactive Biotech Products S.L.Ucollaborator
Study Sites (1)
University of Alicante
San Vicent del Raspeig, Alicante, 03690, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior Lecturer, PhD
Study Record Dates
First Submitted
January 22, 2024
First Posted
February 5, 2024
Study Start
October 10, 2025
Primary Completion
April 30, 2026
Study Completion (Estimated)
December 30, 2026
Last Updated
April 1, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share